On November 6th, the 4th China International Import Expo (hereinafter referred to as "CIIE") witnessed another "Lecheng Buzz". For three consecutive years, the "Hope City Moment" of Hainan Free Trade Port has become an eye-catching landscape at China International Import Expo (CIIE), and it has gained “great achievements”. Under the background that China is implementing its domestic and international “double cycle” strategy, the "circle of friends" of Lecheng at CIIE is also expanding, attracting new and old friends to get together at CIIE. This year, Lecheng Pilot Zone has signed contracts or negotiated with 14 internationally renowned pharmaceutical enterprises, including Danaher, Novartis, AstraZeneca, GE Healthcare, Novo Nordisk, Bayer Healthcare, Danone Asia Pacific, etc., to deepen mutual exchanges and jointly create a new chapter for mutual cooperation.

"Happy" to See "Success": Lecheng is happy to see all parties reap win-win results through cooperation.

On the same day, Lecheng signed a total of six contracts with multinational drug and device manufacturers, including the Hainan Lecheng-Mammotome Breast Biopsy Marker Real World Data Research Project jointly launched by Lecheng Pilot Zone Administration and Danaher Corporation, the strategic cooperation memorandum for the innovation in antibody-conjugated drugs signed by Lecheng Pilot Zone Administration and AstraZeneca and Daiichi Sankyo Company Limited, and strategic cooperation memorandum signed with Bayer, Novartis, Novo Nordisk, deepening the cooperation in the fields of diabetes, real-world research and chronic disease management, as well as the Edison Digital Ecological Hospital Project Cooperation Agreement between Boao Yiling Life Care and GE Healthcare.

Looking back on the three visits to CIIE, Lecheng Pilot Zone has become the most important portal for international advanced medical devices and innovative drugs to enter the Chinese market. With the deepening of exchanges and cooperation through the CIIE platform, international innovative medical products can enter China smoothly through the "green channel" provided by Lecheng Pilot Zone. Up to now, there are nearly 200 international innovative drugs and devices not marketed in China that can be used in Lecheng Pilot Zone.

The cooperation between Lecheng and many international renowned drug and device enterprises started at China International Import Expo. For example, Johnson & Johnson's “Catalys白力士” femtosecond laser system for ophthalmology was discovered at China International Import Expo, and then introduced by Lecheng Pilot Zone according to the Try First policy. It became the second innovative medical device approved by using Lecheng's clinical real-world evidence to assist clinical evaluation. At present, it has been used in several cities across the country. In addition, through cooperation with Boao Lecheng, Boston Science's hyperthermia ablation system for benign prostatic hyperplasia Rezūm has successfully been used to treat about 50 patients, and it was pre-marketed at the current China International Import Expo. 

 
Upgraded Cooperation: Share the Chinese market through the pharmaceutical industry ecosystem built by Lecheng. 

Over the past three years, Lecheng Pilot Zone has drawn more and more attention at China International Import Expo, and its cooperation with major international pharmaceutical leaders has gradually gone deeper. Lecheng's cooperation with partners has already gone beyond the introduction and landing of international innovative medical drugs and devices. This year, the “old friends” of Lecheng, such as Novartis, Danaher, GE Healthcare and AstraZeneca, have started to step into the 2.0 era of cooperation with Lecheng Pilot Zone, focusing on real world research, personnel training, digital healthcare and innovative payment schemes.

On the morning of November 6th, 2021, Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration and Danaher Corporation, a world-renowned pharmaceutical enterprise, jointly launched the Hainan Lecheng-Mammotome Breast Biopsy Marker Real World Data Research Project at the 4th China International Import Expo.

At the China International Import Expo, Lecheng Pilot Zone Administration and Danaher Corporation, a world-renowned pharmaceutical enterprise, jointly launched the Hainan Lecheng-Mammotome Breast Biopsy Marker Real World Data Research Project, aiming at further deepening cooperation and achieving win-win development. In March 2021, Mammotome, a company under Danaher Corporation, successfully perform the world's first operation using Mammotome's two-way vacuum-assisted breast biopsy and peeling system in Boao Lecheng Pilot Zone, Hainan Province, which is also the first operation in the world since the establishment of Lecheng Pilot Zone.

Peng Yang, global vice president of Danaher and president of Danaher China, reviewed the cooperation process between Danaher and Boao Lecheng Pilot Zone, and said,“Under the new pattern of international and domestic double cycles, we will upgrade Danaher's localization strategy in China again, make full use of Boao Lecheng's pioneering advantages and Danaher Corporation's open strategic thinking, and jointly empower in the field of real-world data research, accelerate the marketing process of Danaher's innovative products in China to benefit more Chinese patients.”

Novartis also released the version 2.0 plan to upgrade the cooperation between Boao Lecheng and Novartis: exploring the real world data research system and accelerating innovative research and personnel training.
On November 6th, 2021, Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration and Novartis signed a strategic cooperation memorandum again at the 4th China International Import Expo.

At the 3rd China International Import Expo held last year, Novartis signed a memorandum of strategic cooperation with Lecheng Pilot Zone Administration to accelerate the entry of Novartis's series of innovative products and solutions in Lecheng, so that more Chinese patients can enjoy the world's most advanced treatment method without going abroad. This year, Novartis's three major innovative drugs were tried first in Lecheng Pilot Zone, which not only made it possible for Chinese patients to enjoy the international advanced treatment solution for the first time, but also accelerated the launch of Novartis's innovative products in the Chinese market. In addition, Lecheng Global Special Drug Insurance's 2021 version cover 100 kinds of special drugs; Among 75 overseas special drugs, eight innovative drugs from Novartis are covered, ranking first in quantity among selected peer companies.

At this CIIE, Lecheng Pilot Zone Administration and Novartis signed a strategic cooperation memorandum again, aiming at starting new cooperation and practice in the field of translational medicine and real-world research, and assisting in personnel training and international exchanges. Dan Brindle, president of Novartis Group (China), said,“This strategic cooperation is the 2.0 version of cooperation between Novartis and Boao Lecheng Administration. Both parties will jointly build an advanced scientific research environment and platform, promote the development of translational medicine and real-world research in Boao Lecheng through multi-level and multi-field cooperation, in order to better meet patients' medication needs, help train talents and jointly improve their scientific research capabilities.” 

On the afternoon of November 6th, 2021, Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration and AstraZeneca China joined hands to jointly promote the accelerated introduction of innovative drugs for the treatment of cancers and rare diseases, and carry out the cooperation on the development model research of Internet hospitals in China at the 4th China International Import Expo.

Last year at China International Import Expo, AstraZeneca and Lecheng started cooperation in a number of projects such as Internet hospitals. This year, AstraZeneca, Lecheng Administration and Daiichi-Sankyo (China) Investment signed the Hainan Strategic Cooperation Agreement on the Innovation of Antibody-Drug Conjugates again at the China International Import Expo. The parties will promote pilot cooperation on innovative anti-tumor drugs, including DS8201, a new HER2-targeting antibody-drug conjugate and many other urgently needed imported drugs, as well as real-world research for breast cancer and other diseases to accelerate the introduction of innovative cancer drugs worldwide into China.  

Yuichi Yomasu, President of Daiichi Sankyo China, said “As an R&D enterprise with more than 100 years of innovation, Daiichi Sankyo is committed to developing new therapies for cancer patients by utilizing world-class medical technologies. We are very happy that antibody-drug conjugate (ADC) for breakthrough treatment can be launched in Boao Lecheng Pilot Zone, which is a historic moment.” 

In addition, AstraZeneca also signed the Strategic Cooperation Agreement on Pioneering Steps in Use of Innovative Drugs for Rare Diseases with Lecheng, taking Selumetinib, the world's first targeted drug for neurofibromatosis type 1 as a pilot project in Hainan, further promoting the early use of innovative drugs for rare diseases。 Michael Lai, General Manager at AstraZeneca China, said，“AstraZeneca officially entered the field of rare diseases this year, and we will continue to promote the cooperation with Boao Lecheng in the field of rare diseases, in the hope that we provide better innovative treatment solutions to Chinese clinical medical experts and benefit more patients.”

On November 6th, 2021, at the 4th China International Import Expo (“CIIE" for short), GE Healthcare officially signed the Edison Digital Ecological Hospital Project Cooperation Agreement with Boao Yiling Life Care in Lecheng Pilot Zone, according to which Lecheng and GE Healthcare will jointly build a Digital Eco-Smart Hospital in Lecheng Pilot Zone.

This year at the CIIE, with the cutting-edge digital medical technologies, “Lecheng Wind” swept the medical device exhibition area, attracting many exhibitors. Bo 'ao Yiling Life Care from Lecheng Pilot Zone and GE Healthcare officially signed the Edison Digital Ecological Hospital Project Cooperation Agreement, including the joint construction of a Digital Eco-smart Hospital in Lecheng Pilot Zone. Dai Ying, vice president and chief innovation officer of GE Healthcare China, said that the cooperation field will be extended to medical development form, and we will jointly build a number of remote applications, image research and panoramic display centers, so as to put the AI ecological chain of Edison platform into practice and launch more digital medical applications, thus benefiting the clinic and patients.

Lecheng Pilot Zone Administration also actively visited Johnson & Johnson, Roche, Merck, Danone Asia Pacific and many other enterprises to strengthen the ties with them. For example, Danone's various special medical foods for the treatment of genetic metabolism also appeared at the CIIE. The head of Danone newdihia children's medical nutrition division said that he was looking forward to cooperating with Lecheng on the landing of special medical foods for rare diseases, so as to make up for the market gaps in China and better serve families living with children with rare diseases. Lyu Xiaolei, a member of the Party Committee and deputy director of Lecheng Pilot Zone Administration, said at the CIIE, "Lecheng Pilot Zone has always been a pilot area driven by pioneering, reform and opening-up. At present, Lecheng has preliminarily built an ecological circle for the pharmaceutical industry. All parties involved in the medical ecosystem, including pharmaceutical and medical device companies, medical service providers, commercial insurance and other market players involved in medical fields, can find opportunities for cooperation in Lecheng, an open platform, and share the platform, resources and the huge consumer market of China. We look forward to working with more international leading drug and device companies to jointly promote innovation in the fields of medicine, healthcare and medical insurance, and ultimately benefit Chinese patients.” 

As the only industrial park in China that is open to the outside world in the medical field, Lecheng is accelerating the pace of exploration. The achievements made from the CIIE in the past three years are another example of the continuous release of “spillover effect”of the CIIE, the embodiment of the continuous improvement of the business environment of Hainan Free Trade Port, and the gradual trend towards legalization, internationalization and convenience, and another vivid footnote of Lecheng's active cooperation with all parties to jointly promote innovation. This fully shows that Lecheng is gradually developing a “Lecheng Model” that benefits all parties in the field of medical services. Lecheng will also make full use of the China International Import Expo as an open cooperation platform, deepen cooperation and accelerate the building of a new highland for medical opening-up in Hainan Free Trade Port.